Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis

Andrew J. Haak, Enis Kostallari, Delphine Sicard, Giovanni Ligresti, Kyoung Moo Choi, Nunzia Caporarello, Dakota L. Jones, Qi Tan, Jeffrey Meridew, Ana M.Diaz Espinosa, Aja Aravamudhan, Jessica L. Maiers, Rodney D. Britt, Anja C. Roden, Christina M. Pabelick, Y. S. Prakash, Seyed Mehdi Nouraie, Xiaoyun Li, Yingze Zhang, Daniel J. KassDavid Lagares, Andrew M. Tager, Xaralabos Varelas, Vijay H. Shah, Daniel J. Tschumperlin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tissue fibrosis is characterized by uncontrolled deposition and diminished clearance of fibrous connective tissue proteins, ultimately leading to organ scarring. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have recently emerged as pivotal drivers of mesenchymal cell activation in human fibrosis. Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the G-s-coupled dopamine receptor D1 (DRD1) is preferentially expressed in lung and liver mesenchymal cells relative to other resident cells of these organs. Agonism of DRD1 selectively inhibits YAP/TAZ function in mesenchymal cells and shifts their phenotype from profibrotic to fibrosis resolving, reversing in vitro extracellular matrix stiffening and in vivo tissue fibrosis in mouse models. Aromatic l-amino acid decarboxylase [DOPA decarboxylase (DDC)], the enzyme responsible for the final step in biosynthesis of dopamine, is decreased in the lungs of subjects with idiopathic pulmonary fibrosis, and its expression inversely correlates with disease severity, consistent with an endogenous protective role for dopamine signaling that is lost in pulmonary fibrosis. Together, these findings establish a pharmacologically tractable and cell-selective approach to targeting YAP/TAZ via DRD1 that reverses fibrosis in mice.

Original languageEnglish (US)
Article numbereaau6296
JournalScience translational medicine
Volume11
Issue number516
DOIs
StatePublished - Oct 30 2019

Fingerprint

Dopamine Receptors
Fibrosis
Fibroblasts
Dopamine D1 Receptors
Proteins
Dopamine
Aromatic-L-Amino-Acid Decarboxylases
Lung
Idiopathic Pulmonary Fibrosis
Carboxy-Lyases
Pulmonary Fibrosis
Connective Tissue
Cicatrix
Extracellular Matrix
Regeneration
Homeostasis
Phenotype
Liver
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. / Haak, Andrew J.; Kostallari, Enis; Sicard, Delphine; Ligresti, Giovanni; Choi, Kyoung Moo; Caporarello, Nunzia; Jones, Dakota L.; Tan, Qi; Meridew, Jeffrey; Espinosa, Ana M.Diaz; Aravamudhan, Aja; Maiers, Jessica L.; Britt, Rodney D.; Roden, Anja C.; Pabelick, Christina M.; Prakash, Y. S.; Nouraie, Seyed Mehdi; Li, Xiaoyun; Zhang, Yingze; Kass, Daniel J.; Lagares, David; Tager, Andrew M.; Varelas, Xaralabos; Shah, Vijay H.; Tschumperlin, Daniel J.

In: Science translational medicine, Vol. 11, No. 516, eaau6296, 30.10.2019.

Research output: Contribution to journalArticle

Haak, AJ, Kostallari, E, Sicard, D, Ligresti, G, Choi, KM, Caporarello, N, Jones, DL, Tan, Q, Meridew, J, Espinosa, AMD, Aravamudhan, A, Maiers, JL, Britt, RD, Roden, AC, Pabelick, CM, Prakash, YS, Nouraie, SM, Li, X, Zhang, Y, Kass, DJ, Lagares, D, Tager, AM, Varelas, X, Shah, VH & Tschumperlin, DJ 2019, 'Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis', Science translational medicine, vol. 11, no. 516, eaau6296. https://doi.org/10.1126/scitranslmed.aau6296
Haak, Andrew J. ; Kostallari, Enis ; Sicard, Delphine ; Ligresti, Giovanni ; Choi, Kyoung Moo ; Caporarello, Nunzia ; Jones, Dakota L. ; Tan, Qi ; Meridew, Jeffrey ; Espinosa, Ana M.Diaz ; Aravamudhan, Aja ; Maiers, Jessica L. ; Britt, Rodney D. ; Roden, Anja C. ; Pabelick, Christina M. ; Prakash, Y. S. ; Nouraie, Seyed Mehdi ; Li, Xiaoyun ; Zhang, Yingze ; Kass, Daniel J. ; Lagares, David ; Tager, Andrew M. ; Varelas, Xaralabos ; Shah, Vijay H. ; Tschumperlin, Daniel J. / Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. In: Science translational medicine. 2019 ; Vol. 11, No. 516.
@article{c3133d3ffc114b588111055a92175aa1,
title = "Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis",
abstract = "Tissue fibrosis is characterized by uncontrolled deposition and diminished clearance of fibrous connective tissue proteins, ultimately leading to organ scarring. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have recently emerged as pivotal drivers of mesenchymal cell activation in human fibrosis. Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the G-s-coupled dopamine receptor D1 (DRD1) is preferentially expressed in lung and liver mesenchymal cells relative to other resident cells of these organs. Agonism of DRD1 selectively inhibits YAP/TAZ function in mesenchymal cells and shifts their phenotype from profibrotic to fibrosis resolving, reversing in vitro extracellular matrix stiffening and in vivo tissue fibrosis in mouse models. Aromatic l-amino acid decarboxylase [DOPA decarboxylase (DDC)], the enzyme responsible for the final step in biosynthesis of dopamine, is decreased in the lungs of subjects with idiopathic pulmonary fibrosis, and its expression inversely correlates with disease severity, consistent with an endogenous protective role for dopamine signaling that is lost in pulmonary fibrosis. Together, these findings establish a pharmacologically tractable and cell-selective approach to targeting YAP/TAZ via DRD1 that reverses fibrosis in mice.",
author = "Haak, {Andrew J.} and Enis Kostallari and Delphine Sicard and Giovanni Ligresti and Choi, {Kyoung Moo} and Nunzia Caporarello and Jones, {Dakota L.} and Qi Tan and Jeffrey Meridew and Espinosa, {Ana M.Diaz} and Aja Aravamudhan and Maiers, {Jessica L.} and Britt, {Rodney D.} and Roden, {Anja C.} and Pabelick, {Christina M.} and Prakash, {Y. S.} and Nouraie, {Seyed Mehdi} and Xiaoyun Li and Yingze Zhang and Kass, {Daniel J.} and David Lagares and Tager, {Andrew M.} and Xaralabos Varelas and Shah, {Vijay H.} and Tschumperlin, {Daniel J.}",
year = "2019",
month = "10",
day = "30",
doi = "10.1126/scitranslmed.aau6296",
language = "English (US)",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "516",

}

TY - JOUR

T1 - Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis

AU - Haak, Andrew J.

AU - Kostallari, Enis

AU - Sicard, Delphine

AU - Ligresti, Giovanni

AU - Choi, Kyoung Moo

AU - Caporarello, Nunzia

AU - Jones, Dakota L.

AU - Tan, Qi

AU - Meridew, Jeffrey

AU - Espinosa, Ana M.Diaz

AU - Aravamudhan, Aja

AU - Maiers, Jessica L.

AU - Britt, Rodney D.

AU - Roden, Anja C.

AU - Pabelick, Christina M.

AU - Prakash, Y. S.

AU - Nouraie, Seyed Mehdi

AU - Li, Xiaoyun

AU - Zhang, Yingze

AU - Kass, Daniel J.

AU - Lagares, David

AU - Tager, Andrew M.

AU - Varelas, Xaralabos

AU - Shah, Vijay H.

AU - Tschumperlin, Daniel J.

PY - 2019/10/30

Y1 - 2019/10/30

N2 - Tissue fibrosis is characterized by uncontrolled deposition and diminished clearance of fibrous connective tissue proteins, ultimately leading to organ scarring. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have recently emerged as pivotal drivers of mesenchymal cell activation in human fibrosis. Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the G-s-coupled dopamine receptor D1 (DRD1) is preferentially expressed in lung and liver mesenchymal cells relative to other resident cells of these organs. Agonism of DRD1 selectively inhibits YAP/TAZ function in mesenchymal cells and shifts their phenotype from profibrotic to fibrosis resolving, reversing in vitro extracellular matrix stiffening and in vivo tissue fibrosis in mouse models. Aromatic l-amino acid decarboxylase [DOPA decarboxylase (DDC)], the enzyme responsible for the final step in biosynthesis of dopamine, is decreased in the lungs of subjects with idiopathic pulmonary fibrosis, and its expression inversely correlates with disease severity, consistent with an endogenous protective role for dopamine signaling that is lost in pulmonary fibrosis. Together, these findings establish a pharmacologically tractable and cell-selective approach to targeting YAP/TAZ via DRD1 that reverses fibrosis in mice.

AB - Tissue fibrosis is characterized by uncontrolled deposition and diminished clearance of fibrous connective tissue proteins, ultimately leading to organ scarring. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have recently emerged as pivotal drivers of mesenchymal cell activation in human fibrosis. Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the G-s-coupled dopamine receptor D1 (DRD1) is preferentially expressed in lung and liver mesenchymal cells relative to other resident cells of these organs. Agonism of DRD1 selectively inhibits YAP/TAZ function in mesenchymal cells and shifts their phenotype from profibrotic to fibrosis resolving, reversing in vitro extracellular matrix stiffening and in vivo tissue fibrosis in mouse models. Aromatic l-amino acid decarboxylase [DOPA decarboxylase (DDC)], the enzyme responsible for the final step in biosynthesis of dopamine, is decreased in the lungs of subjects with idiopathic pulmonary fibrosis, and its expression inversely correlates with disease severity, consistent with an endogenous protective role for dopamine signaling that is lost in pulmonary fibrosis. Together, these findings establish a pharmacologically tractable and cell-selective approach to targeting YAP/TAZ via DRD1 that reverses fibrosis in mice.

UR - http://www.scopus.com/inward/record.url?scp=85074369001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074369001&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aau6296

DO - 10.1126/scitranslmed.aau6296

M3 - Article

C2 - 31666402

AN - SCOPUS:85074369001

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 516

M1 - eaau6296

ER -